Osteoporosis: Therapy
Challenges in implementing and maintaining osteoporosis therapy
... of osteoporosis and fracture risk in different patient ...chronic therapy, despite concerns about or the actual occurrence of side ...despite therapy, and patients who experience GI side ...
11
<p>Pharmacological Therapy of Osteoporosis: What’s New?</p>
... anti-osteoporosis therapy, also considering some limitations in the reliability of diagnostic tools to monitor the treatment response, such as the bone turnover markers ...
7
Osteoporosis: the current status of mesenchymal stem cell-based therapy
... cell therapy for osteoporosis, AD-MSCs were reported to function as an effective autologous cell-based approach for the treatment of ...SAMP6 osteoporosis mice showed significant improvement in ...
20
Associations between the 2007 Medicare reimbursement reduction for bone mineral density testing and osteoporosis drug therapy patterns of female Medicare beneficiaries
... new osteoporosis drug therapy (not restarting drug therapy) during the look-back period with one of the US Food and Drug Administration (FDA)-approved medications (BP, selective estrogen receptor ...
7
Patients’ adherence to osteoporosis therapy
... their osteoporosis medications, so some of the themes that emerged might have arisen from patients’ experiences with non-osteo- porosis ...of osteoporosis, which might have made them more motivated than ...
9
Reasons for not initiating osteoporosis therapy among a managed care population
... We conducted a cross-sectional mail survey of women naïve to osteoporosis medications with claims-based evidence of recent osteoporosis-related medical services. Candidates for the survey were identified ...
10
Review of Bone Turn over Biomarkers for Early Diagnose of Osteoporosis
... for osteoporosis as there are many other diseases that can raise the urine dPYR level, including osteomalacia, hyperparathyroidism, thyrotoxicosis and certain inflammatory conditions like Paget’s disease, ...
8
High-Dosage Intravenous Calcium Therapy for Osteoporosis and Osteomalacia in Anticonvulsant Therapy With Hypomobilization
... Two of the patients showed healing of rickets after two and four months of treatment with vitamin D2 1,000 u/day, oral calcium and phosphorus supplement.. Approx-.[r] ...
8
<p>Transient Osteoporosis of the Hip: Risk and Therapy</p>
... The time needed for full recovery was 5.8 weeks for those who underwent drilling, and 48.3 weeks for three patients receiving conservative treatment.. The other two patients who were tre[r] ...
8
Management of glucocorticoid-induced osteoporosis: prevalence, and emerging treatment options
... serum testosterone levels prior to therapy. Lumbar spine BMD, but not hip BMD, was significantly increased (nearly 4%) after 12 months of monthly intramuscular testoster- one injections; in addition, there was an ...
11
Turner Syndrome and Osteoporosis: Mechanisms and Prognosis
... prevent osteoporosis must be used, such as ensuring adequate calcium intake and am- ple weight-bearing activities, focusing on preventing in- juries and avoiding overtreatment with thyroid hor- ...drome, ...
7
A systematic review and meta-analysis of bone metabolism in prostate adenocarcinoma
... bisphosphonate therapy (n = 33); the same cohort was previously analyzed (n = 2); or the bone mineral density, t or z-scores or osteoporosis/ osteopenia rate was not shown (n = ...
10
Evaluation of teriparatide treatment in adults with osteogenesis imperfecta
... teriparatide therapy, there was an anabolic pattern of change in remodeling markers that mimicked those observed in previous studies of teriparatide therapy in osteoporosis ...in osteoporosis ...
9
Menopause, mood and memory : the effect of hormone replacement therapy on mood and everyday memory in mid life women : a thesis presented in partial fulfilment of the requirements for the degree of Master of Arts in Psychology at Massey University
... While hormone replacement therapy was initially prescribed for mid-life women to alleviate the somatic symptoms of menopause, and subsequently to reduce the incidence of osteoporosis and[r] ...
157
Characteristics of patients initiating raloxifene compared to those initiating bisphosphonates
... initiating therapy with a ...raloxifene therapy were younger and had a lower burden of comorbid illness than patients ini- tiating bisphosphonate ...prescribed therapy for the prevention, rather than ...
9
The differential effects of bisphosphonates, SERMS (selective estrogen receptor modulators), and parathyroid hormone on bone remodeling in osteoporosis
... replacement therapy (ERT) has been reported to be clinically useful in preventing bone loss in postmenopausal osteoporosis (Lindsay 1976; Kalu et al ...
10
Atypical subtrochanteric femoral shaft fractures: role for mechanics and bone quality
... Bisphosphonates are highly eff ective agents for reducing osteoporotic fractures in women and men, decreasing fracture incidence at the hip and spine up to 50%. In a small subset of patients, however, these agents have ...
8
Assessment of Bone Acquisition in Childhood and Adolescence
... of osteoporosis and an underestimation of the amount of ...of osteoporosis on the basis of dual-energy x-ray absorptiometry ...that osteoporosis has its antecedents in childhood and the demand for ...
7
Clinical role of bisphosphonate therapy
... All data from randomized controlled trials (RCTs) so far demonstrate that BPs are an effective treatment in PMO, as summarized in Table 1. However, there is some evidence to suggest that there are differences in efficacy ...
15
Bisphosphonates Zoledronate and Alendronate for the Management of Postmenopausal Osteoporosis
... In 1993, a randomized, double blinded, controlled clinical trial, the fracture intervention trial was laid out by Black et al. , 1993 [70]. 6457 osteoporotic women were recruited and divided into two sub-studies ...
19